Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Young head and neck cancer patients are at increased risk of developing oral mucositis and trismus

Full text
Author(s):
Morais-Faria, Karina [1] ; Palmier, Natalia Rangel [2] ; Correia, Jaqueline de Lima [2] ; de Castro Junior, Gilberto [3] ; Dias, Reinaldo Brito [4] ; Pinto, Henrique da Graca [4] ; Lopes, Marcio Ajudarte [2] ; Prado Ribeiro, Ana Carolina [1] ; Brandao, Thais Bianca [1] ; Santos-Silva, Alan Roger [1, 2]
Total Authors: 10
Affiliation:
[1] ICESP FMUSP, Inst Canc Estado Sao Paulo, Dent Oncol Serv, Sao Paulo - Brazil
[2] Univ Estadual Campinas, Piracicaba Dent Sch, Semiol Area, Oral Diag Dept, 901 Av Limeira, BR-13414903 Piracicaba, SP - Brazil
[3] Univ Sao Paulo, Sao Paulo State Canc Inst ICESP, Clin Oncol Serv, Sch Med, Sao Paulo - Brazil
[4] Univ Sao Paulo, Dept Maxillofacial Surg Prosthesis & Traumatol, Sao Paulo - Brazil
Total Affiliations: 4
Document type: Journal article
Source: SUPPORTIVE CARE IN CANCER; v. 28, n. 9, p. 4345-4352, SEP 2020.
Web of Science Citations: 0
Abstract

Objectives To evaluate cancer treatment-related toxicities in young head and neck cancer (HNC) patients. Material and methods A total of 44 patients were included in the present retrospective cohort study, which was designed to access oral toxicities of cancer treatment in young (< 45 years of age, Group I,n = 22) and old (> 58 years of age, Group II,n = 22) HNC patients with similar tumor stage and treatment protocols. Oral mucositis (OM), xerostomia, dysphagia, dysgeusia, trismus, and radiodermatitis were assessed during days 7th, 21st, and 35th of head and neck radiotherapy (HNRT) according to previously validated scales (World Health Organization criteria and the National Cancer Institute and Common Terminology Criteria for Adverse Events version 4.0). Results Patients from both groups showed high incidence and severity of oral toxicities by the end of the HNRT with OM (81.9% (Group I); 63.6% (Group II)) and xerostomia (72.6% (Group I); 77.2% (Group II)) being the most prevalent toxicities. No differences regarding xerostomia, dysphagia, dysgeusia, and radiodermatitis incidences or severity could be observed between groups. However, higher incidences and severity of OM at 21st and 35th fractions (odds ratio = 2.22 and 5.71, respectively) and trismus at 21st and 35th fractions (odds ratio = 6.17 and 14.5, respectively) were observed throughout the treatment in young patients when compared to older patients (p < 0.01 andp < 0.05, respectively). Conclusion Young HNC patients are more affected by cancer treatment-related OM and trismus despite the similarities in clinical staging and treatment protocols with elderly patients. (AU)

FAPESP's process: 18/02233-6 - Oncological safety of the use of intraoral and extraoral photobiomodulation in patients with oral cavity and oropharyngeal squamous cell carcinoma
Grantee:Alan Roger dos Santos Silva
Support type: Regular Research Grants
FAPESP's process: 16/22862-2 - Impact of age in radiation-induced oral toxicities of young patients with oral cancer
Grantee:Jaqueline de Lima Correia
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 18/04657-8 - Salivary protein markers of radiation-related oral toxicites
Grantee:Natália Rangel Palmier
Support type: Scholarships in Brazil - Doctorate